These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 660847)

  • 1. High fiber diet in hyperlipemia. Comparison with cholestyramine treatment in type IIA hyperlipoproteinemia.
    Palumbo PJ; Briones ER; Nelson RA
    JAMA; 1978 Jul; 240(3):223-7. PubMed ID: 660847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of hyperlipoproteinemia to cholestyramine resin.
    Fallon HJ; Woods JW
    JAMA; 1968 Jun; 204(13):1161-4. PubMed ID: 5694692
    [No Abstract]   [Full Text] [Related]  

  • 4. Lecithin: cholestrol acyl transfer rate and high density lipoproteins in plasma during dietary and cholestyramine treatment of type IIa hyperlipoproteinaemia.
    Wallentin L
    Eur J Clin Invest; 1978 Dec; 8(6):383-9. PubMed ID: 217692
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-fibre diets for diabetic and hypertriglyceridemic patients.
    Anderson JW
    Can Med Assoc J; 1980 Nov; 123(10):975-9. PubMed ID: 6256046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 8. A double-blind, randomized, controlled trial of the effects of two eggs per day in moderately hypercholesterolemic and combined hyperlipidemic subjects taught the NCEP step I diet.
    Knopp RH; Retzlaff BM; Walden CE; Dowdy AA; Tsunehara CH; Austin MA; Nguyen T
    J Am Coll Nutr; 1997 Dec; 16(6):551-61. PubMed ID: 9430083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial.
    Levy RI; Fredrickson DS; Stone NJ; Bilheimer DW; Brown WV; Glueck CJ; Gotto AM; Herbert PN; Kwiterovich PO; Langer T; LaRosa J; Lux SE; Rider AK; Shulman RS; Sloan HR
    Ann Intern Med; 1973 Jul; 79(1):51-8. PubMed ID: 4578640
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia.
    Sweeney ME; Fletcher BJ; Rice CR; Berra KA; Rudd CM; Fletcher GF; Superko RS
    Am J Med; 1991 Apr; 90(4):469-73. PubMed ID: 2012087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic failure in familial type II hyperlipoproteinemia.
    Witters LA; Herbert PN; Shulman RS; Krauss RM; Levy RI
    Metabolism; 1976 Sep; 25(9):1017-26. PubMed ID: 183084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Type II primary hyperlipoproteinemia: effect of dietary treatment and cholestyramine on serum lipids and lipoproteins].
    Vaverková H; Kubasta M; Zmeskal A; Procházka J; Vrublowský P; Podivínský
    Vnitr Lek; 1976 Jan; 22(1):73-83. PubMed ID: 175564
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of blood lipids by guar crispbread.
    Jenkins DJ; Reynolds D; Slavin B; Leeds AR; Waller AL; Jepson LM
    Proc Nutr Soc; 1979 Sep; 38(2):86A. PubMed ID: 504205
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol.
    Jenkins DJ; Wolever TM; Rao AV; Hegele RA; Mitchell SJ; Ransom TP; Boctor DL; Spadafora PJ; Jenkins AL; Mehling C
    N Engl J Med; 1993 Jul; 329(1):21-6. PubMed ID: 8389421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High protein diet complements resin therapy of familial hypercholesterolemia.
    Wolfe BM; Giovannetti PM
    Clin Invest Med; 1992 Aug; 15(4):349-59. PubMed ID: 1516292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential hyperlipemia with xanthomatosis: effects of cholestyramine and clofibrate.
    Roe DA
    Arch Dermatol; 1968 Apr; 97(4):436-45. PubMed ID: 5643239
    [No Abstract]   [Full Text] [Related]  

  • 19. Xanthomatosis and hyperlipoproteinemia; a review.
    Polano MK
    Dermatologica; 1974; 149(1):1-9. PubMed ID: 4372111
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cholestyramine as a cholesterol lowering preparation. A clinical evaluation].
    Bye A; Brox D
    Tidsskr Nor Laegeforen; 1976 Jun; 96(16):928-9. PubMed ID: 779134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.